DBV Technologies Shares Stumble to €3.36 After Widened Quarterly Loss
The stock of the French biotech company declined sharply during the session to €3.36, following the announcement of its first quarter 2026 results last Thursday. The movement is part of a slightly bearish Parisian market, with the CAC 40 down by 0.46%. Year-over-year, the stock still shows a gain of 120.9%.
DBV Technologies published its first quarter 2026 financial results on April 30. The net loss increased to $47.6 million, amid a significant rise in R&D expenses related to the progress of the Viaskin Peanut program. Concurrently, the company confirmed a cash reserve of $229 million as of March 31, which covers its needs until the second quarter of 2027 thanks to the full exercise of warrants issued during the private placement in March 2025. The regulatory timeline remains a central element of the case: the biotech plans two biologics license application submissions in 2026, one for the age group 4-7 years and the other for 1-3 years, as well as a new phase 2 study in infants aged 6 to 12 months.
Stock Price Approaches Lower Bollinger Band
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
At €3.36, the stock is nearing the lower Bollinger band set at €3.31, and is just above the support at €3.34. The RSI at 44 remains in the neutral zone, with no clear oversold signal despite today's drop. The price has fallen below the 50-day moving average (€3.60) but remains well above the 200-day moving average at €2.74, reflecting the strong increase accumulated over the past year. The next key date is the mixed general meeting on June 3, 2026, before the half-year results scheduled for July 29.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
